THIS SITE IS FOR US HEALTHCARE PROFESSIONALS ONLY

Quadramet is indicated for relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radonuclide bone scan More

• 62% to 72% of patients experienced relief¹
• Moderate, predictable, and transient myelosuppression²

• 16-week duration of relief with a single 1.0 mCi/kg injection¹
• Acts systemically to target multiple lesion sites³

REFERENCES:

1. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16:1574-1581.
2. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63:940-945.
3. Quadramet (samarium Sm-153 lexidronam injection) prescribing information. April 2008

QUADRAMET® causes bone marrow suppression. Before QUADRAMET is administered, consideration should be given to the patient's current clinical and hematologic status and bone marrow response history to treatment with myelotoxic agents. Because of the unknown potential for additive effects on bone marrow, QUADRAMET should not be given concurrently with chemotherapy or external beam radiation therapy unless the clinical benefits outweigh the risks.

Home | EUSA Pharma | Safety Information | Prescribing Information | Reimbursement Information
Freedom To Do More | Bone Metastases | Patient Types | News & Clinical Updates | Patient Resources | Web Resources
Contact Us | Site Map | Privacy Policy | Terms of Use

Copyright © 2010 EUSA Pharma (USA), Inc. All rights reserved